GMDA - Slight Bullish Divergence. Could Recover Market Losses
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
SHORT INTEREST
30.41K 07/31/19
P/E Current
-0.33
P/E Ratio (with extraordinary items)
-1.65
Average Recommendation: BUY
Average Target Price: 18.00
SHORT INTEREST
30.41K 07/31/19
P/E Current
-0.33
P/E Ratio (with extraordinary items)
-1.65
Average Recommendation: BUY
Average Target Price: 18.00
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.